-+ 0.00%
-+ 0.00%
-+ 0.00%
GlucoTrack delays third-quarter report over derivative valuations
Share
Listen to the news
GlucoTrack delays third-quarter report over derivative valuations
  • GlucoTrack delayed its Form 10-Q for the quarter ended September 30, 2026, pending accounting and valuations involving derivative liabilities.
  • The report is expected within the five-calendar-day extension period.
  • Net loss is expected to widen by approximately $13.3 million to $29 million, reflecting the Lokahi merger and financing transactions.
  • Operating expenses are projected to rise to approximately $17.2 million from $12.6 million a year earlier.
  • Net financing-related expenses are forecast to increase to approximately $11.8 million from $3.1 million a year earlier.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-052670), on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending